Lung - Refresher 2022
Major decreases in cancer mortality have been driven by improvements in the management of lung cancer. The explanation for these survival improvements is complex but largely driven by the increasing use of systemic therapies in early stage disease such as immunotherapy. Additionally, local ablative therapies in advanced stage disease are also improving outcomes. Translation of these practices into community based setting is important. This educational activity will help participants to better apply new treatment strategies so that patient outcomes can be enhanced. Additionally, it will provide insight into where current deficits in management remain and future studies to answer these questions.
This activity is available from May 2, 2022, through 11:59 p.m. Eastern time on May 1, 2025.
This activity was originally recorded at ASTRO’s virtual 2022 ASTRO Annual Refresher Course, March 27-27, 2022.
The activity is designed to meet the interests of radiation oncologists, radiation oncology residents, medical oncologists, physicists, radiation therapists and dosimetrists.
Upon completion of this activity, learners should be able to:
Explain the increasing use of immunotherapy with non-metastatic lung cancer.
Apply principles of when radiotherapy is appropriate (and when it is not) in advanced lung cancer.
Explore the evolving treatment options for locally advanced, resectable lung cancer.
Russell Hales, MD is employed by Johns Hopkins University and has no financial relationships with a commercial interest.
The person(s) above served as the developer(s) of this activity. Additionally, the Education and CME/MOC Committees had control over the content of this activity.
All relevant relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 1.50 Certificate of AttendanceThis activity was designated for 1.50 AMA PRA Category 1 Credit™.
- 1.50 SA-CME
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing medical education for physicians.
The American Society for Radiation Oncology (ASTRO) designates this for a maximum of 1.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity meets the American Board of Radiology's criteria for a self-assessment activity in the ABR's Maintenance of Certification program. Participation in this course in combination with the successful completion of the corresponding assessment and course evaluation adheres to the guidelines established by the ABR for 1.50 self-assessment credits.
ASTRO members must log in to the ASTRO website to view and receive the discounted member rate.
- Nonmember: $105
- Member: $55
No refunds, extensions, or substitutions will be made for participants, including those who for any reason, have not completed the course by the end of the qualification date. The qualification date for each course is listed in the course catalog on the ASTRO website under availability.
Participants using ASTRO's online courses to satisfy the requirement of a Maintenance of Certification (MOC) program should verify the number, type and availability dates of any course before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased courses that do not align with their MOC requirement.
The course and its materials will only be available on the ASTRO website for that 3 year period regardless of purchase date. At the expiration of the qualification, participants will no longer have access to the course or its materials. ASTRO reserves the right to remove a course before the end of its qualification period.
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.